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ABSTRACT 
In an open trial on manic patients, side-effects of carbamazepine, lithium and haloperidol were 
evaluated weekly over a 4-week period. The total side-effects with the three drugs were not 
significantly different, but the rate of amelioration of the same was best for lithium and least for 
haloperidol. It was indicative that lithium was better tolerated drug than the other two. 
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INTRODUCTION 
Lithium (Li) and carbamazepine (CBZ) are the 
accepted first line anti-manic drugs (Kaplan et al 
1994). Haloperidol (HP) previously, was one of 
the accepted modes of treatment for mania 
(Shopsin et al 1975) and is being still used widely 
for the acute treatment of mania. All these agents 
have annoying and obtruding side-effects . The 
side-eifect profile of these agents often dictates 
their use in patients, as they can prevent further 
raising of the doses and/or affect the compliance 
of the patient. As part of the study dealing with 
their efficacy (the results of which have been sent 
for publication elsewhere), we aimed to study 
their side-effect profile, and thereby the compara-
tive tolerability of these agents. 
MATERIAL AND METHODS: 
In an open study, adult patients from the out 
patient section of the Department of Psychiatry, 
K.G.'s Medical College, Lucknow diagnosed as 
bipolar disorder - mania according to DSM-III-R 
criteria (APA.1987) were randomly allocated to 
one of the three treatment groups - Li, CBZ and 
HP. Informed consent was taken from all the 
patients. Baseline investigations included com-
plete hemogram, liver function and renal function 
tests. The selected patients were rated on Bech-
Rafaelson Mania Scale (Bech et al 1978) on days 
0,7.14,2land 28 and side - effect checklist on 
days 7,14,21, and 28. The side-effect checklist 
consisted of pooled items from three sources -
WHO Multicentric Collaborative Study (WHO 
1986) for HP, role of hereditary, clinical and 
pharmacokinetic factors for prediction of lithium 
(WHO 1988) for Li and Myler's Textbook of 
side-effects (1988) for CBZ. 
On day 'O' the selected patients were started 
on either CBZ (200mg/d, which was built upto 
800 mg/d by the end of first week), or HP (15 
mg/d) or Li (900mg/d). Oral trihexyphenidyl 
(6mg/d) was given with haloperidol, and in all the 
groups oral diazepam was given on SOS basis. 
The patients continued on the same medication, 
subject to appearance of serious side-effects 
when the dosage were reduced, till day 21. By 
this time, if a reduction of 50% of the initial 
BRMS score was not achieved, the doses of 
CBZ, Li and HP were increased to 1200 mg/d, 
1200 mg/d and 20mg/d respectively. 
To compare the changes in side-effect ratings 
for both intragroup and intergroup comparisons 
paired 't' test "vis used. 
RESULTS Ai\ D DISCUSSION: 
Out of 61 patients selected for the study only 
43 (Males =35, female =8) completed the study. 
The 18 patients dropped out for various reasons 
(left against medical advice = 10, required other 
medication = 4, withdrew their consent = 4), but 
none due to serious side-effects. 
The majority of side-effects with all the 3 
agents, were observed during the initial week of 
therapy and their frequency and intensity pro-
gressively decreased with the duration of the 
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trial. CBZ commonly produced drowsiness, 
diplopia/nystagmus, constipation and ataxia dur-
ing the first week, and also slurred spech and 
vertigo during the second week. This probably 
was due to the fact that the maximum dosage of 
CBZ were reached only by the end of first week. 
Nausea/vomiting, diarrhea and tremors were 
seen in the Li group in the first week, and toxic 
confusional state, ataxia and constipation in the 
2nd week. However, all these symptoms subsid-
ed within the next week and by day 28 none of the 
patients reported any adverse effects. 
The anticholinergic property of haloperidol was 
responsible for producing dry mouth, constipa-
tion, rigidity, akathisia and slurred speech. 
The dosage that was started on day 0 for HP 
and Li and those reached at day 7 for CBZ, were 
maintained till die end of die trial, and no decre-
ments had to be made for die side -effects. Thus 
the drugs were well tolerated and this is borne out 
by statistical analysis which showed that mere 
was no statistically significant difference in the 
adverse effects at weekly intervals between the 
groups. 
The intragroup comparisons show that the 
side -effects diminished over the weeks. This 
was highly significant for Li (p>.001) at all levels 
of comparison and moderately so for HP and CBZ 
(table -1). A faster reduction of side-effects 
speaks of better compliance and more flexibility 
in dosage regime which appears best for Li fol-
lowed by HP and CBZ. 
Mil  hi: 
Draft 
CBZ 
U 
HP 
df 
14 
11 
IS 
CHANGES IN SIDE-EFFECT SCORES ROM IASB1NE 
7-14 
MMI(S.D) 
0.4(1.9) 
1.1(1.1) 
0.9(2.4) 
t 
1.16 
14**** 
1.42 
7-21 
MaonliD) 
2.3(3.4) 
13(1.5) 
14(14) 
I 
V* 
s.r 
15** 
7-28 
Meon(S.D) 
0.9(2.4) 
UttU 
2.0(2.9) 
t 
27* 
sr 
ir 
For an value* N for CBZ- IS, Li-12, HP=16 
*p>.01 • 
**p>.001 
In our study we were handicapped by don-
availability of serum levels of die drugs, which 
constrained us in correlating the appearance of 
side-effects with it. Secondly, the sample size 
was small, this being a time bound study. 
The authors have not come across any study 
which directly deals with the issue and therefore 
are not able to compare their results with any 
other study. However, as the side-effects of any 
drug are as important as its therapeutic efficacy, 
it was considered an issue important enough to 
address separately. 
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